reports
GW Pharmaceuticals recognised for leadership in prescription cannabis-...
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen’s Award for Enterpr...
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceut...
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today. The proposals required to be approved by GW’s shareholders in order to complete the acquisition were each approved. In addition, the non-binding, advisory proposal to approve certain compensation arrangemen...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex – Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved c...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex – Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved c...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Presen...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis CARLSBAD, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cann...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex – If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cann...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex – If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financ...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress – Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year – – Previously announced agreement to be acquired by Jazz Pharmaceuticals; transaction expected to close in Q2 2021 – LONDON and CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and ...
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2...
GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones - Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year -- Total Epidiolex® preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year –- Pivotal US clinical program for nabiximols in MS spasticity underway. Initial data expected in 2021 - LONDON and CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GW Pha...
CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th A...
CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group) under the same headline, please note the time of the conference and breakout session have changed. The conference will be held Tuesday, January 12, 2021 at 10:00 am ET (7:00 am PT). The breakout session will follow at 10:20 am ET (7:20 am PT). Complete corrected release follows: GW Pharmaceuticals plc (NASDAQ: GWP...
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Ora...
JAMA Neurology Publishes Phase 3 Study of EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated with Tuberous Sclerosis Complex EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results of the company’s po...
GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & P...
GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference on Thursday, December 10, 2020 at 11:00am EST. A live audio webcast of the presentation will be available through GW’s...
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral...
Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting - Meeting Highlights Include New Long-Term Data in Tuberous Sclerosis Complex - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that a variety of data, including long-term data in the treatment of tuberous sclerosis complex (TSC) and in multiple ...
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conf...
GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at in the Investors section under Events & Presentat...
Greenwich Biosciences to Present Analysis of Three Clinical Studies of...
Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly - Results from analysis of three Phase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed CARLSBAD, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Greenwich Bioscien...
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Co...
GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at in the Investors section under Events & Presen...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results a...
GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress - Total revenue increased 51 percent to $137.1 million – - Epidiolex for seizures associated with TSC launched in the U.S. -- Nabiximols Phase 3 program in MS spasticity now recruiting -- Conference call today at 8:30 a.m. EST - LONDON and CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for...
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for M...
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols, known as Sativex® outside of the U.S. and...
- MarketLine Department
Summit Therapeutics Plc - Mergers & Acquisitions (M&A), Partnerships &...
Summary Marketline's Summit Therapeutics Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Summit Therapeutics Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of t...
GW Pharmaceuticals plc to Report Financial Results and Operational Pro...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020 LONDON and CARLSBAD, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on November 3rd, 2020 its financial results and operational progress for the third quarter ending September 30th, 2020. GW will al...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.